Tag: Intracellular Sigma Peptide (ISP)
A systemically injectable peptide, which may make it possible to restore lost functions in spinal cord injury patients, is moving toward clinical trials in early 2020.
The treatment, which was developed by Jerry Silver, a professor of neurosciences at Case Western Reserve University’s School of Medicine and advisor for NervGen Pharma, is the culmination of decades of work, and in pre-clinical studies, it has shown robust results in animal models.
Injuries to the spinal cord can cause permanent paralysis and even lead to death, with little to no hope of regaining lost functions once the trauma has occurred.
Dr Jerry Silver and his team at Case Western Reserve University Medical School, USA, have been working to understand why nerves that are damaged through spinal injury don’t regenerate and to identify non-invasive, easy to administer strategies that can promote robust functional recovery.
The immune system of spinal cord injury patients can be controlled using a family of therapeutic stem cells, according to findings published in Scientific Reports.
Researchers from Case Western Reserve University studied the therapeutic stem cells, known as multipotent adult progenitor cells (MAPC) in order to observe their qualities and effects on spinal cord injury patients’ immune systems.
NIH-funded scientists developed a promising new drug that may lead to spinal cord injury treatments.
Case Western Reserve Scientists Design Intracellular Sigma Peptide (ISP) to Promote Functional Recovery Following Spinal Cord Injury
Case Western Reserve scientists have developed a new chemical compound that shows extraordinary promise in restoring function lost to spinal cord injury. The compound, which the researchers dubbed intracellular sigma peptide (ISP), allowed paralyzed muscles to activate in more than 80 percent of the animals tested. The remarkable study, partly funded by the National Institutes of Health, appears in the December 3 edition of the journal Nature.